Bayer HealthCare and Compugen have signed an oncology collaboration and license agreement to research, develop and commercialise a new cancer treatment.

The partnership is focused on antibody-based therapeutics for cancer immunotherapy, targeting two novel immune checkpoint regulators discovered by Compugen.

The Bayer HealthCare executive committee member and global drug discovery head professor Andreas Busch said the company is committed to translating the science of cancer research into effective therapies, helping people affected by cancer live longer and improve their quality of life.

"Antibody-based immunotherapies are promising approaches in oncology, which can stimulate the body’s own immune cells to fight cancer cells," Busch said.

"Immunotherapy is one of our focus areas in oncology research. We are looking forward to expanding our portfolio in this area through partnering with Compugen."

According to the deal, both organisations will jointly conduct a preclinical research programme, whereas Bayer will be responsible for further development and global commercialisation of potential cancer therapeutics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Compugen will earn be an upfront payment of $10m and is eligible for more than $500m in potential milestone payments for both programmes, excluding milestone payments of up to $30m associated with preclinical activities.

Compugen will also be eligible to receive sales-based royalties of the products resulting from the collaboration.

Commenting on the partnership, Compugen president and CEO Dr Anat Cohen-Dayag said: "We believe that the prediction and validation of these two targets, through the use of our broadly applicable predictive discovery infrastructure, provides additional validation for our long-term commitment to establishing this unique capability."